Oncohema Key

All about dexamethasone testing in Cushing’s syndrome

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on All about dexamethasone testing in Cushing’s syndrome

Introduction There are more than 60 years since Liddle first used dexamethasone, one of the most potent synthetic glucocorticoids, at a dose of 0.5 mg every 6 hours for 2…

read more

Nonneoplastic hypercortisolism (pseudo-CS): Causes and long-term issues

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Nonneoplastic hypercortisolism (pseudo-CS): Causes and long-term issues

Introduction Endogenous hypercortisolism is one of the most challenging diagnostic problems in clinical endocrinology. Chronic hypercortisolism, responsible for Cushing’s syndrome (CS), is usually of neoplastic origin and secondary to autonomous…

read more

Cushing’s disease: Pituitary tumors causing CS—Diagnosis and treatment

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Cushing’s disease: Pituitary tumors causing CS—Diagnosis and treatment

Introduction Cushing’s disease (CD) is the most common form of endogenous hypercortisolism and is characterized by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, with corticotroph tumors representing up to 15% of…

read more

Factitious Cushing syndrome and factitious Cushing syndrome-by-proxy: Cases, diagnosis, and outcomes

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Factitious Cushing syndrome and factitious Cushing syndrome-by-proxy: Cases, diagnosis, and outcomes

Introduction This chapter will provide a broad overview about factitious disorder or factitious disorder imposed on another (i.e., by proxy) to raise awareness about this rare disorder in patients evaluated…

read more

Exogenous (iatrogenic) Cushing syndrome: Most frequent uses of glucocorticoids and outcomes, including recommendations for recovery (postchemotherapy, asthma treatments, chronic use on rheumatoid, and/or skeletal disorders)

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Exogenous (iatrogenic) Cushing syndrome: Most frequent uses of glucocorticoids and outcomes, including recommendations for recovery (postchemotherapy, asthma treatments, chronic use on rheumatoid, and/or skeletal disorders)

Introduction Due to their strong antiinflammatory and immunosuppressive actions, glucocorticoids (GCs) are one of the cornerstone treatments for the first-line therapy of various inflammatory and autoimmune disorders. However, notwithstanding their…

read more

Animal models of CS: What do they teach us?

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Animal models of CS: What do they teach us?

Introduction Endogenous Cushing’s syndrome (CS), or hypercortisolism, is a rare medical condition (up to 10 per million) caused by glucocorticoid excess [ ]. This condition may be difficult to recognize…

read more

Identification of Cushing’s syndrome (CS) and its history from Harvey Cushing to today

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Identification of Cushing’s syndrome (CS) and its history from Harvey Cushing to today

Introduction The history of Cushing’s syndrome (CS) dates back to the late 1800s when the first cases were reported, even though they were not recognized as such at the time….

read more

Endogenous Cushing’s syndrome: Causes and genetics

May 17, 2026 by drzezo in ENDOCRINOLOGY Comments Off on Endogenous Cushing’s syndrome: Causes and genetics

Disclosure Statement CT received research funding on treatment of abnormal growth hormone secretion by Pfizer. CF has nothing to disclose. Introduction Cushing’s syndrome (CS) refers to exposure of the body…

read more